Drug intelligence / Profile preview

paliperidone + trimethoprim

Development stage
Unknown
Modality
Small Molecules
Administration
Oral
01

Overview

paliperidone + trimethoprim is a combination of two distinct pharmaceutical drugs: paliperidone, an atypical antipsychotic primarily used for schizophrenia and schizoaffective disorders, and trimethoprim, an antifolate antibiotic used primarily to treat bacterial infections such as urinary tract infections. This combination is not recognized as a marketed combination drug and there is no evidence of it being developed, approved, or widely used as a fixed-dose combination for any indication. Paliperidone acts mainly by antagonizing dopamine D2 and serotonin 5-HT2A receptors in the brain, while trimethoprim inhibits bacterial dihydrofolate reductase, interfering with bacterial folic acid synthesis. When co-administered, clinical studies indicate no clinically significant pharmacokinetic interaction between the two agents[1][5].

02

Targets

HTR2A (Serotonin receptor 5-HT2A)DHFR (Dihydrofolate reductase)HTR1D (5-hydroxytryptamine receptor 1D)DRD4 (Dopamine D4 Receptor)DRD2 (Dopamine D2 Receptor)HTR7 (5-hydroxytryptamine receptor 7)HTR2B (5-Hydroxytryptamine Receptor 2B)

Beyond the preview

Go deeper on paliperidone + trimethoprim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paliperidone + trimethoprim.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call